The estimated Net Worth of David Jakeman is at least $231 ezer dollars as of 14 February 2024. Mr Jakeman owns over 2,660 units of Chimerix Inc stock worth over $121,460 and over the last 5 years he sold CMRX stock worth over $109,099.
Mr has made over 10 trades of the Chimerix Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,660 units of CMRX stock worth $2,766 on 14 February 2024.
The largest trade he's ever made was exercising 5,250 units of Chimerix Inc stock on 5 April 2021 worth over $12,338. On average, Mr trades about 1,937 units every 77 days since 2019. As of 14 February 2024 he still owns at least 141,232 units of Chimerix Inc stock.
You can see the complete history of Mr Jakeman stock trades at the bottom of the page.
David Jakeman is the Exec. Director of Fin. & Accounting and Principal Accounting Officer at Chimerix Inc.
Mr Jakeman is 44, he's been the Exec. Director of Fin. & Accounting and Principal Accounting Officer of Chimerix Inc since . There are 12 older and no younger executives at Chimerix Inc. The oldest executive at Chimerix Inc is Catherine Gilliss, 71, who is the Independent Director.
David's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.
Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex és Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.
led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed
Chimerix Inc executives and other stock owners filed with the SEC include: